Eli Lilly has announced an additional investment of $4.5bn across two of its three sites in Indiana in the US, bringing the company’s total Indiana capital expansion commitments since 2020 to more than $21bn.
The additional commitment comes in light of Lilly’s evolving pipeline and anticipated demand for its medicines. The investment will incorporate new process designs and technologies at Lilly Lebanon API in Indiana, one of the company’s future active pharmaceutical ingredient sites, as well as Lilly Lebanon Advanced Therapies in Indiana, its first dedicated genetic medicine manufacturing facility.
Lilly Lebanon Advanced Therapies is designed to support both clinical and commercial production of advanced therapies that target disease at the genetic level and will include a full spectrum of genetic medicine modalities from research-stage development through large-scale commercial supply.
Designing and building for these modalities required developing new manufacturing processes without established commercial precedent. This facility is the first of three planned sites on the Lebanon campus, which will also include Lilly Lebanon API and the Lilly Medicine Foundry.
Lebanon, Indiana is the cornerstone of Lilly’s domestic manufacturing buildout. In 2024, the company announced plans to make both Zepbound (tirzepatide) and Mounjaro (tirzepatide), injectable medications for weight management and type 2 diabetes respectively, at its Lebanon API site.
The investment expands that commitment further, including planned production of Foundayo (orforglipron), Lilly’s first FDA-approved, once-daily pill for weight loss that can be taken without food or water restrictions, and retatrutide, an investigational triple hormone receptor agonist in late-stage development for obesity and cardiometabolic disease.
“Lilly’s legacy of firsts in Indiana continues – and the best measure of that legacy is what we do next,” said David A. Ricks, Lilly chair and CEO.
Since 2020, Lilly has committed more than $50bn in capital expansion in the US.